54741_Image_jpeg.jpg
Study Demonstrates Importance and Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Assessment of Heart Failure
17 févr. 2022 08h00 HE | Daxor Corporation
Daxor’s BVA-100® Shown to Provide Unique and Actionable Data for Addressing Heart Failure Oak Ridge, TN, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in...
54741_Image_jpeg.jpg
Daxor Corporation to Commence Trading on The Nasdaq Capital Market On February 2, 2022
20 janv. 2022 16h05 HE | Daxor Corporation
Oak Ridge, TN, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that it will commence trading on The Nasdaq...
54741_Image_jpeg.jpg
DAXOR AWARDED NEW PATENT FOR BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES
04 janv. 2022 08h00 HE | Daxor Corporation
Method Patent Covers Blood Volume Analysis Technology to Evaluate and Guide Treatment Decisions in Multiple Medical Conditions Oak Ridge, TN, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation...
54741_Image_jpeg.jpg
Daxor Corporation Receives $200K Matching Fund Award from Launch Tennessee
01 oct. 2021 08h30 HE | Daxor Corporation
The SBIR/STTR Matching Fund Grant Will Advance the Company’s Innovation and Commercialization Efforts, and Job Creation Oak Ridge, TN, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE:...
54741_Image_jpeg.jpg
Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Heart Failure Patients at Key Scientific Society Meeting
14 sept. 2021 08h30 HE | Daxor Corporation
Data from Three New Studies and Two Ongoing Trials Presented at the Heart Failure Society of America Annual Scientific Meeting 2021 Data Highlight Importance of Blood Volume Analysis in Providing...
54741_Image_jpeg.jpg
Daxor Corporation Announces 61% Increase in Q1 2021 Sales Revenue and Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.
13 mai 2021 08h30 HE | Daxor Corporation
NEW YORK, NY, May 13, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announced a Q1 2021 increase in revenue of 61% in...
54741_Image_jpeg.jpg
Daxor Corporation to Present at the 13th Annual LD Micro Main Event 2020
09 déc. 2020 08h30 HE | Daxor Corporation
NEW YORK, NY, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
54741_Image_jpeg.jpg
Daxor to Present at the Inaugural Sepsis Alliance Summit
15 sept. 2020 08h30 HE | Daxor Corporation
NEW YORK, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
54741_Image_jpeg.jpg
Daxor to Present at H.C. Wainwright 22nd Annual Global Investment Conference
10 sept. 2020 08h30 HE | Daxor Corporation
NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
54741_Image_jpeg.jpg
Daxor Corporation Announces Appointment of Henry D. Cremisi, MD, FACP and Joy Goudie, Esq. to the Company’s Board of Directors
30 juin 2020 08h00 HE | Daxor Corporation
NEW YORK, June 30, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...